Cargando…

Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer

BACKGROUND: The aim of this study was to explore the short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer (ER). METHODS: Eighty-eight patients with ER cancer and 82 healthy controls who had completed a full course of inac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Rui, Liu, Li, Pan, Qingbo, Liu, Jin, Tan, Jiahe, Deng, Juan, Deng, Qin, Lin, Zijin, Chen, Min, Peng, Mingli, Ren, Hong, Ming, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637626/ https://www.ncbi.nlm.nih.gov/pubmed/36353624 http://dx.doi.org/10.3389/fimmu.2022.1028246

Ejemplares similares

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
por: Li, Tong, et al.
Publicado: (2022)

Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer
por: Han, Yuling, et al.
Publicado: (2022)

The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity
por: Keshtkar-Jahromi, Maryam, et al.
Publicado: (2020)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial
por: Hu, Jialei, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults
por: Wu, Yufei, et al.
Publicado: (2023)

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients
por: Yang, Lei, et al.
Publicado: (2023)

Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China
por: Chen, Yaping, et al.
Publicado: (2022)

Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines
por: Duan, Binwei, et al.
Publicado: (2022)

Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial
por: Xia, Shengli, et al.
Publicado: (2022)

Effect of seasonal coronavirus immune imprinting on the immunogenicity of inactivated COVID-19 vaccination
por: Yin, Di, et al.
Publicado: (2023)

Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review
por: Bansal, Amit, et al.
Publicado: (2021)

A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2023)

The safety and immunogenicity to inactivated COVID-19 vaccine in patients with hyperlipemia
por: Yang, Lei, et al.
Publicado: (2023)

Enhanced Immunogenicity of a Whole-Inactivated Influenza A Virus Vaccine Using Optimised Irradiation Conditions
por: Singleton, Eve Victoria, et al.
Publicado: (2021)

Evaluation of the Safety and Immunogenicity of Duck-Plague Virus gE Mutants
por: Ning, Yaru, et al.
Publicado: (2022)

Identification of Potentially Therapeutic Immunogenic Peptides From Paracoccidioides lutzii Species
por: Silva, Leandro B. R., et al.
Publicado: (2021)

Assessment of Immunogenicity of Adjuvanted Quadrivalent Inactivated Influenza Vaccine in Healthy People and Patients With Common Variable Immune Deficiency
por: Kostinova, Aristitsa Mikhailovna, et al.
Publicado: (2020)

Immunogenicity and protective efficacy of OmpA subunit vaccine against Aeromonas hydrophila infection in Megalobrama amblycephala: An effective alternative to the inactivated vaccine
por: Zhang, Minying, et al.
Publicado: (2023)

Immunogenicity and safety of concomitant administration of the chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: A multicenter, randomized, non-inferiority, controlled trial
por: Sun, Xiang, et al.
Publicado: (2022)

Antibody response and safety of inactivated SARS-CoV-2 vaccines in chronic hepatitis B patients with and without cirrhosis
por: Cao, Huanhuan, et al.
Publicado: (2023)

SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World’s Population
por: Patarroyo, Manuel A., et al.
Publicado: (2022)

Vaccination Against SARS-CoV-2 in Lung Transplant Recipients: Immunogenicity, Efficacy and Safety
por: Svorcova, Monika, et al.
Publicado: (2022)

Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3–9-month intervals following two-dose inactivated vaccine (CoronaVac)
por: Liao, Yuting, et al.
Publicado: (2022)

Evaluation of safety and immunogenicity of duck-plague virus gC/gE double gene deletion
por: Ruan, Peilin, et al.
Publicado: (2022)

Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents
por: Leung, Daniel, et al.
Publicado: (2023)

Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis
por: Li, Zejun, et al.
Publicado: (2022)

Evaluating SARS-CoV-2 antibody reactivity to natural exposure and inactivated vaccination with peptide microarrays
por: Zheng, Peiyan, et al.
Publicado: (2023)

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
por: He, Qian, et al.
Publicado: (2021)

Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China
por: Li, Mingzhu, et al.
Publicado: (2023)

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
por: Kandeil, Ahmed, et al.
Publicado: (2021)

Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity
por: Sedaghat, Nahad, et al.
Publicado: (2023)

Peptide adjacent to glycosylation sites impacts immunogenicity of glycoconjugate vaccine
por: Ma, Zhongrui, et al.
Publicado: (2017)

Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides
por: Puig, Montserrat, et al.
Publicado: (2021)

Analysis of neutralizing antibodies to COVID-19 inactivated or subunit recombinant vaccines in hospitalized patients with liver dysfunction
por: Li, Hu, et al.
Publicado: (2023)

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
por: Nurpeisova, Ainur, et al.
Publicado: (2022)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

A Short Peptide of Autotransporter Ata Is a Promising Protective Antigen for Vaccination Against Acinetobacter baumannii
por: Sun, Peng, et al.
Publicado: (2022)

Artificial Intelligence Applied to in vitro Gene Expression Testing (IVIGET) to Predict Trivalent Inactivated Influenza Vaccine Immunogenicity in HIV Infected Children
por: Cotugno, Nicola, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_39umhcn5jq9fgopqelu81gn0fn